Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Heart failure with preserved ejection fraction in Asia
on behalf of the ASIAN-HF Investigators
Medicine - Veteran's Administration Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
155
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Heart failure with preserved ejection fraction in Asia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Asia
100%
Comorbidity
71%
Southeast Asian
42%
Atrial Fibrillation
42%
Obesity
28%
Anemia
28%
South Asian
28%
China
14%
India
14%
Japan
14%
South Asia
14%
Diabetes
14%
Heart Failure
14%
Chronic Kidney Disease
14%
Indonesia
14%
Hypertension
14%
Coronary Artery Disease
14%
High Risk
14%
Trial Design
14%
Singapore
14%
South-East Asia
14%
Taiwan
14%
Hong Kong
14%
Patients with Heart Failure
14%
Clinical Characteristics
14%
Thailand
14%
Left Ventricular Hypertrophy
14%
Young Patients
14%
Philippines
14%
Left Ventricular Ejection Fraction
14%
High Burden
14%
Cardiac Remodeling
14%
High Prevalence
14%
Adverse Outcomes
14%
Asian Patients
14%
Low Prevalence
14%
Cardiac Outcomes
14%
Cardiac Geometry
14%
Northeast Asia
14%
Northeast Asians
14%
Echocardiographic Parameters
14%
Comorbidity Burden
14%
Malaysia
14%
Asian Region
14%
Concentric Remodeling
14%
Hypertrophy/remodeling
14%
Public Health Measures
14%
Global Public Health Problem
14%
Echocardiographic Outcomes
14%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Comorbidity
85%
Atrial Fibrillation
42%
Prevalence
28%
Anemia
28%
Chronic Kidney Failure
14%
Heart Ventricle Remodeling
14%
Coronary Artery Disease
14%
Congestive Heart Failure
14%
Adverse Outcome
14%
Heart Left Ventricle Hypertrophy
14%
Diseases
14%
Hypertension
14%